

Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica


Supplemental Figure 1: Result of meta-analysis for SALT30, regarding treatment with brepocitinib and ritlecitinib.




Supplemental Figure 2: Result of meta-analysis for SALT50, regarding treatment with baricitinib, brepocitinib and ritlecitinib.



Supplemental Figure 3: Result of meta-analysis for SALT75, regarding treatment with baricitinib, brepocitinib and ritlecitinib.




Supplemental Figure 4: Result of meta-analysis for SALT90, regarding treatment with baricitinib, brepocitinib and ritlecitinib.




Supplemental Figure 5: Result of meta-analysis for SALT100, regarding treatment with baricitinib, brepocitinib and ritlecitinib.

	JAK inhibitor		Control		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
King et al. (phase II) baricitinib 2 mg once daily	3	27	0	28	15.8%	0.11 [-0.02, 0.24]	
King et al. (phase II) baricitinib 4 mg once daily	7	27	0	28	10.7%	0.26 [0.09, 0.43]	
King et al. (phase IIa) brepocitinib 60+30 mg	6	47	0	47	21.8%	0.13 [0.03, 0.23]	
King et al. (phase IIa) ritlecitinib 200+50 mg	2	48	0	47	31.4%	0.04 [-0.03, 0.11]	
Yassky et al. (phase IIa) brepocitinib 60+30 mg	1	16	0	12	10.8%	0.06 [-0.11, 0.23]	
Yassky et al. (phase IIa) ritlecitinib 200+50 mg	2	18	0	12	9.5%	0.11 [-0.07, 0.30]	-
Total (95% CI)		183		174	100.0%	0.10 [0.04, 0.17]	•
Total events	21		0				
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 7.74$, $df = 5$ ($P = 0.17$); $I^2 = 35\%$						-1 -0.5 0 0.5 1	
Test for overall effect: $Z = 3.21 (P = 0.001)$							Favours [control] Favours [JAK inhibitor]

Supplemental Figure 6: Result of meta-analysis for SALT50, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.



Supplemental Figure 7: Result of meta-analysis for SALT75, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.



Supplemental Figure 8: Result of meta-analysis for SALT90, regarding treatment with CTP-543 (deuruxolitinib), and baricitinib.

